If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  EFNS CONGRESS: Zyprexa Reduces Symptoms In Alzheimer’s Patients SEVILLE, SPAIN -- Sept. 22, 1998 -- Study results show that Eli Lilly & Co.’s Zyprexa® (olanzapine) is able to improve psychosis and behavioural disturbances in patients with Alzheimer’s disease. The study results were presented at the third congress of the European Federation of Neurological Societies. Zyprexa significantly reduced agitation, delusions and hallucinations compared to placebo, without the adverse side-effect profile associated with other antipsychotic agents. The drug is currently licensed for the management of schizophrenia and related psychotic disorders. Debilitating psychosis and behavioural disturbances are often associated with Alzheimer’s and have a substantial impact on quality of life for both patients and their caregivers. Approximately half of patients seen in outpatients clinics and three quarters of those in nursing homes suffer from significant behavioural disturbances and the incidence of psychotic symptoms can be as high as 73 percent, with patients experiencing delusions, paranoia and hallucinations, the researchers explained. The study was a multicentre, randomised, double-blind, placebo-controlled trial, which examined the effects of Zyprexa on psychosis and behavioural disturbances in 206 nursing home patients with moderate to severe Alzheimer’s over a six-week period. The results show that treatment with the drug is significantly better than treatment with placebo and the response rate of the Zyprexa 5 mg treatment group is nearly twice that of the placebo group. Related Links: Zyprexa, Eli Lilly & Co.
|
